{"id":"NCT02480153","sponsor":"Pfizer","briefTitle":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-25","primaryCompletion":"2016-08-31","completion":"2017-12-06","firstPosted":"2015-06-24","resultsPosted":"2017-09-26","lastUpdate":"2019-01-23"},"enrollment":597,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"PF-06410293","otherNames":["Adalimumab-Pfizer"]},{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["Adalimumab-European Union, Humira®"]}],"arms":[{"label":"PF-06410293","type":"EXPERIMENTAL"},{"label":"Adalimumab","type":"ACTIVE_COMPARATOR"}],"summary":"The study will assess the efficacy, safety, and immunogenicity of PF-06410293 and adalimumab in combination with methotrexate in subjects with moderately to severly active rheumatoid arthritis who have had an inadequate response to methotrexate.\n\nIn an additional optional portion of the study, during open label Treatment Period 3 (TP3), a subset of subjects used a Prefilled Pen (PFP) to administer up to 3 injections of their study treatment (PF-06410293) at home.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1","timeFrame":"Week 12","effectByArm":[{"arm":"Period 1: PF-06410293","deltaMin":68.35,"sd":null},{"arm":"Period 1: Adalimumab-EU","deltaMin":71.33,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":183,"countries":["United States","Australia","Brazil","Bulgaria","Colombia","Czechia","Estonia","Georgia","Germany","Hungary","Japan","Lithuania","Mexico","New Zealand","Peru","Poland","Russia","Serbia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["36180101","35304684","34563243","33883254","33263165","30111357"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5381002&StudyName=A%20Study%20Of%20PF-06410293%20%28Adalimumab-Pfizer%29%20And%20Adalimumab%20%28Humira%29%20In%20Combination%20With%20Methotrexate%20In%20Subjects%20With%20Active%20Rheumatoid"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":297},"commonTop":["Viral upper respiratory tract infection","Rheumatoid arthritis","Nasopharyngitis"]}}